Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

346
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
346
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

309
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
309
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

571
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
571
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

998
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
998
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

667
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
667
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.7K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-dose linezolid during BPaL implementation for pre-extensively drug-resistant TB or failure/intolerance of rifampicin-resistant TB regimens.

IJTLD open·2026
Same author

Experiences from Ukraine in expanding TB infection diagnosis and treatment, including for drug-resistant TB.

IJTLD open·2026
Same author

High efficacy of BPaL among patients infected with <i>Mycobacterium tuberculosis</i> lineage 1 in the Philippines.

IJTLD open·2026
Same author

The time is now: making the case for compassionate use/pre-approval access to new TB drugs.

IJTLD open·2025
Same author

Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment.

Public health action·2025
Same author

Treatment success rate and time to culture conversion under a prospective BPaL cohort study.

IJTLD open·2025

Related Experiment Video

Updated: Dec 3, 2025

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.3K

Introducing bedaquiline: experiences from the Challenge TB Project.

C G Edwards1, D F Wares2, G Dravniece2

  • 1The Global Fund to Fight AIDS Tuberculosis and Malaria, Geneva, Switzerland.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|October 31, 2020
PubMed
Summary

Introducing bedaquiline (BDQ) for drug-resistant tuberculosis (DR-TB) required significant time and a systematic approach. Successful scale-up involved policy changes, healthcare worker training, and improved lab networks, leading to increased patient enrollment and treatment success.

More Related Videos

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.1K

Related Experiment Videos

Last Updated: Dec 3, 2025

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.3K
A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.1K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pharmacology

Background:

  • Drug-resistant tuberculosis (DR-TB) presents a significant global health challenge.
  • The World Health Organization endorsed bedaquiline (BDQ) in 2013 for eligible DR-TB patients.
  • The Challenge TB (CTB) project aimed to facilitate BDQ introduction in supported countries.

Purpose of the Study:

  • To analyze the processes and outcomes of introducing bedaquiline-containing regimens in 23 countries.
  • To identify critical interventions and challenges associated with BDQ implementation.
  • To assess the impact of BDQ on patient enrollment and treatment outcomes.

Main Methods:

  • Retrospective review of project reports from 2016 to mid-2019.
  • Analysis of data on implementation processes, patient enrollment, and interim treatment outcomes.
  • Examination of country-level data from 23 Challenge TB supported nations.

Main Results:

  • BDQ introduction averaged 2 years, with rapid scale-up in Ethiopia and Kyrgyzstan.
  • Key interventions included advocacy, policy revision, healthcare worker capacity building, and laboratory strengthening.
  • 9398 patients received BDQ; 71% achieved culture negativity by 6 months.
  • Challenges included regulatory coordination, drug quantification, and drug safety reporting.

Conclusions:

  • Successful bedaquiline introduction necessitates a systematic, programmatic strategy.
  • Initial time investment is crucial for achieving scale-up, coverage, and sustainability.
  • National TB Programmes play a vital role in the ownership and long-term success of BDQ implementation.